This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A novel prognostic model based on pyroptosis-related genes for multiple myeloma
BMC Medical Genomics Open Access 23 February 2023
-
Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma
Journal of Translational Medicine Open Access 18 December 2018
-
Systematic expression alteration analysis of master reprogramming factor OCT4 and its three pseudogenes in human cancer and their prognostic outcomes
Scientific Reports Open Access 04 October 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Accession codes
References
Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32.
Stewart AK, Fonseca R . Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339–6344.
Bergsagel P, Kuehl W, Zhan F, Sawyer J, Barlogie B, Shaughnessy J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303.
Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005; 23: 7296–7306.
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199.
Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003; 102: 1588–1594.
Malumbres M, Barbacid M . To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222–231.
Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005; 65: 11345–11353.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hanamura, I., Huang, Y., Zhan, F. et al. Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia 20, 1288–1290 (2006). https://doi.org/10.1038/sj.leu.2404253
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404253
This article is cited by
-
A novel prognostic model based on pyroptosis-related genes for multiple myeloma
BMC Medical Genomics (2023)
-
High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma
The Pharmacogenomics Journal (2020)
-
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
Journal of Hematology & Oncology (2018)
-
Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma
Journal of Translational Medicine (2018)
-
Systematic expression alteration analysis of master reprogramming factor OCT4 and its three pseudogenes in human cancer and their prognostic outcomes
Scientific Reports (2018)